Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

A reduction in BCR-ABL1/ABL1(IS) transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple BCR-ABL1 th...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Mol Sci
Главные авторы: Stella, Stefania, Zammit, Valentina, Vitale, Silvia Rita, Pennisi, Maria Stella, Massimino, Michele, Tirrò, Elena, Forte, Stefano, Spitaleri, Antonio, Antolino, Agostino, Siragusa, Sergio, Accurso, Vincenzo, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Russo, Sabina, Malato, Alessandra, Mineo, Giuseppe, Musso, Maurizio, Porretto, Ferdinando, Martino, Bruno, Di Raimondo, Francesco, Manzella, Livia, Vigneri, Paolo, Stagno, Fabio
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6539817/
https://ncbi.nlm.nih.gov/pubmed/31064152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20092226
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы